School of Public Health, Peking University, Beijing, China.
Peking University Clinical Research Institutes, Beijing, China.
BMC Complement Med Ther. 2023 Oct 27;23(1):388. doi: 10.1186/s12906-023-04218-y.
Hot flashes are the common and debilitating symptom among prostate cancer (PCa) patients undergoing androgen deprivation therapy (ADT). Strong evidence from multiple rigorously designed studies indicated that pharmacological option such as venlafaxine provides partial relief, but the tolerability is poor when dose is not tapered. Hence, alternative therapy is needed. Previous studies reported that acupuncture may be helpful in the management of hot flashes. However, the insufficient randomized controlled trial limited the quality of evidence.
Five hospitals will recruit 120 acupuncture naïve patients with moderate-to-severe hot flashes after prostate cancer received ADT in China from February 2023 to December 2024. Participants will be randomly 2:1:1 allocated to the 18 sessions of verum acupuncture at true acupuncture points plus usual care, 18 sessions of non-penetrating sham acupuncture at non-acupuncture points plus usual care, or usual care alone over 6 weeks. The primary outcome measure is the change of mean weekly hot flashes symptom severity score (HFSSS) at the end of treatment compared with baseline.
We will be able to measure the effectiveness of acupuncture for patients with PCa suffering from ADT-induced hot flashes and whether acupuncture is superior to sham acupuncture and usual care. The proposed acupuncture treatment might provide an alternative option for those patients.
Clinicaltrials.gov (NCT05069467).
热潮红是接受雄激素剥夺疗法(ADT)的前列腺癌(PCa)患者常见且使人虚弱的症状。多项精心设计的严格研究的有力证据表明,药物选择,如文拉法辛,提供部分缓解,但剂量未逐渐减少时耐受性差。因此,需要替代疗法。先前的研究报告称,针灸可能有助于管理热潮红。然而,随机对照试验不足限制了证据的质量。
2023 年 2 月至 2024 年 12 月,中国的五家医院将招募 120 名接受 ADT 后出现中度至重度热潮红的针灸新手 PCa 患者。参与者将被随机分为 2:1:1 组,分别接受 18 次真针灸点的真针灸加常规护理、18 次非穿透假针灸点的非针灸加常规护理或单独接受常规护理 6 周。主要结局指标是治疗结束时与基线相比每周平均热潮红症状严重程度评分(HFSSS)的变化。
我们将能够衡量针灸对接受 ADT 引起的热潮红的 PCa 患者的有效性,以及针灸是否优于假针灸和常规护理。拟议的针灸治疗可能为这些患者提供另一种选择。
Clinicaltrials.gov(NCT05069467)。